AKLI(Delisted)
Akili·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 2
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About AKLI
Akili, Inc.
A company that developing therapeutic designed to target cognitive impairment at its source in brain diseases
71 Commercial Street, Mailbox 312, Boston, MA 02109
--
Akili, Inc., was incorporated on December 1, 2011 under the laws of the State of Delaware. The company is a leading digital medicine company, pioneering the development of cognitive therapy through game-changing technology. The company's approach to developing and commercializing technology aimed directly at brain physiology establishes a new class of medicine — drugs that can be validated by clinical trials like drugs or medical devices, but experienced like entertainment.
Company Financials
EPS
AKLI has released its 2024 Q1 earnings. EPS was reported at -0.12, versus the expected -0.14, beating expectations. The chart below visualizes how AKLI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
AKLI has released its 2024 Q1 earnings report, with revenue of 383.00K, reflecting a YoY change of 238.94%, and net profit of -9.76M, showing a YoY change of 52.86%. The Sankey diagram below clearly presents AKLI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
